MSH2 Antibody (G-7): sc-376501
- MSH2 Antibody (G-7) is a mouse monoclonal IgG2a κ, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 1-300 of MSH2 of human origin
- recommended for detection of MSH2 of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG2a BP-HRP is the preferred secondary detection reagent for MSH2 Antibody (G-7) for WB applications. This reagent is now offered in a bundle with MSH2 Antibody (G-7) (see ordering information below).
QUICK LINKS
MSH2 Antibody (G-7) is a mouse monoclonal IgG2a light chain antibody that detects MSH2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MSH2 plays a crucial role in the DNA mismatch repair (MMR) pathway, which is essential for maintaining genomic stability by correcting errors that occur during DNA replication. MSH2 (G-7) antibody enables detection of a protein vital for preventing mutation accumulation that can lead to various cancers, including hereditary nonpolyposis colorectal cancer (HNPCC). MSH2 forms a heterodimer with MSH6 or MSH3, which is critical for recognizing and binding to mismatched DNA, thereby initiating the repair process. The significance of MSH2 extends beyond HNPCC, as mutations have been implicated in a range of other malignancies characterized by microsatellite instability, highlighting MSH2′s importance in tumorigenesis. Anti-MSH2 antibody (G-7) serves as an invaluable tool for researchers studying DNA repair mechanisms and MSH2′s implications in cancer biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MSH2 Antibody (G-7) References:
- Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. | Pritchard, CC., et al. 2014. Nat Commun. 5: 4988. PMID: 25255306
- Expressional analysis of MLH1 and MSH2 in breast cancer. | Malik, SS., et al. 2019. Curr Probl Cancer. 43: 97-105. PMID: 30149959
- MSH2 Overexpression Due to an Unclassified Variant in 3'-Untranslated Region in a Patient with Colon Cancer. | Liccardo, R., et al. 2020. Biomedicines. 8: PMID: 32575404
- A Novel Splice-Site Mutation in MSH2 Is Associated With the Development of Lynch Syndrome. | Li, J., et al. 2020. Front Oncol. 10: 983. PMID: 32637358
- MLH1, MSH2, MRE11, and XRCC1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma. | Donís, SP., et al. 2021. Appl Immunohistochem Mol Morphol. 29: 613-618. PMID: 33734109
- Invasive ACTH-producing pituitary gland neoplasm secondary to MSH2 mutation. | Loughrey, PB., et al. 2021. Cancer Genet. 256-257: 36-39. PMID: 33866195
- Characteristic mutations induced in the small intestine of Msh2-knockout gpt delta mice. | Aoki, Y., et al. 2021. Genes Environ. 43: 27. PMID: 34225823
- Pleomorphic rhabdomyosarcoma in a young adult harboring a novel germline MSH2 variant. | Tomida, A., et al. 2022. Hum Genome Var. 9: 8. PMID: 35260566
- The mismatch-repair proteins MSH2 and MSH6 interact with the imprinting control regions through the ZFP57-KAP1 complex. | Acurzio, B., et al. 2022. Epigenetics Chromatin. 15: 27. PMID: 35918739
- Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome-associated MSH2-deficient endometrial cancer. | Bowen, MB., et al. 2024. bioRxiv.. PMID: 38915709
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MSH2 Antibody (G-7) | sc-376501 | 200 µg/ml | $322.00 | |||
MSH2 Antibody (G-7): m-IgG2a BP-HRP Bundle | sc-546060 | 200 µg Ab; 10 µg BP | $361.00 |